Natco Pharma to price Risdiplam at ₹15,900

The update was given by the company in response to various queries it received on the launch and pricing of the product
| Photo Credit:
cueapi

Natco Pharma has decided to price Risdiplam, indicated for the treatment of rare genetic disorder Spinal Muscular Atrophy (SMA), at₹15,900.

In an update on the legal proceedings on the Risdiplam launch in India, Natco said Delhi High Court had denied Roche’s plea for an injunction against the company for the drug. 

However, Roche has appealed the decision before the Appellate Bench of the Delhi High Court who has currently directed it to maintain the status quo. 

“Due to the pendency of the proceedings before the court, the company does not wish to comment on the status of the proceedings. However, it has been the stand of the company that it intends to launch the drug only after and subject to successful clarity from the Appellate Bench of the Delhi High Court which is expected shortly,’‘ Natco said. 

The drug maker decided to price the product at ₹15,900 consistent with its stand before the court. It also intended to offer discounts to certain deserving patients through its patient access programme.

The update was given by the company in response to various queries it received on the launch and pricing of the product, the release added. 

Published on April 8, 2025